Literature DB >> 20567005

Can oral bisphosphonates really reduce the risk of breast cancer in healthy women?

Michael Gnant.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20567005     DOI: 10.1200/JCO.2010.29.6327

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor.

Authors:  A Bertaina; A Zorzoli; A Petretto; G Barbarito; E Inglese; P Merli; C Lavarello; L P Brescia; B De Angelis; G Tripodi; L Moretta; F Locatelli; I Airoldi
Journal:  Oncoimmunology       Date:  2016-09-27       Impact factor: 8.110

Review 2.  Individualizing osteoporosis therapy.

Authors:  S Silverman; C Christiansen
Journal:  Osteoporos Int       Date:  2012-01-05       Impact factor: 4.507

3.  Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer.

Authors:  Genevieve M Monsees; Kathleen E Malone; Mei-Tzu C Tang; Polly A Newcomb; Christopher I Li
Journal:  J Natl Cancer Inst       Date:  2011-10-21       Impact factor: 13.506

4.  Exposure to bisphosphonates and risk of cancer: a protocol for nested case-control studies using the QResearch primary care database.

Authors:  Yana Vinogradova; Carol Coupland; Julia Hippisley-Cox
Journal:  BMJ Open       Date:  2012-01-12       Impact factor: 2.692

5.  Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case-control studies using two primary-care databases.

Authors:  Y Vinogradova; C Coupland; J Hippisley-Cox
Journal:  Br J Cancer       Date:  2013-07-18       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.